$12.39
-0.13-1.04%
At close: -
$12.39
0.000.00%
After Hours: Dec 20, 4:00 PM EDT
Comments
Loading...
Latest news for Greenwich LifeSciences (NASDAQ:GLSI) Stock
Greenwich LifeSciences Stock (NASDAQ: GLSI)
Categories: All
Tuesday, November 26, 2024
Friday, August 23, 2024
Thursday, August 01, 2024
Thursday, July 25, 2024
Wednesday, June 26, 2024
Friday, June 14, 2024
Wednesday, May 22, 2024
Monday, April 22, 2024
Monday, March 25, 2024
Wednesday, February 28, 2024
Tuesday, February 27, 2024
Thursday, February 22, 2024
Tuesday, February 20, 2024
Wednesday, February 14, 2024
Monday, October 02, 2023
Friday, July 21, 2023
Monday, April 10, 2023
Wednesday, January 11, 2023
Friday, November 25, 2022
Monday, October 24, 2022
Monday, October 17, 2022
Monday, October 10, 2022
Monday, October 03, 2022
Monday, September 19, 2022
Monday, September 12, 2022
Monday, August 22, 2022
Thursday, August 11, 2022
Monday, August 08, 2022
Wednesday, August 03, 2022
Wednesday, July 13, 2022
Tuesday, July 12, 2022
- Crude Oil Prices Fall Sharply; Greenwich LifeSciences Shares Spike Higher
- Here's Why Greenwich Lifesciences Shares Are Popping Off Today
- U.S. Stocks Turn Higher; PepsiCo Posts Upbeat Q2 Results
- Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session
- Greenwich LifeSciences shares are trading hig...
- Why Markets Are Trading Mixed; US Small Business Optimism Tumbles To This Level
- The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner
- Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed
Monday, July 11, 2022
- UPDATE: Greenwich LifeSciences Says FDA Is Currently Reviewing Manufacturing Data, Has Sent Co. Follow Up Questions To Which Co. Has Responded; Co. Says 3rd Lot Was Manufactured In Commercial Facility On Automated Filling Line
- Greenwich LifeSciences Says Completed Last Steps Of Manufacturing GP2, Says Released Three Clinical Lots Of GP2 Drug Product That Co. Believes Meet All Release Specifications
- Greenwich LifeSciences Announces Suspension of Share Repurchase Program